AUP Aurinia Pharmaceuticals Inc.

Aurinia to Participate in Upcoming Investor Healthcare Conferences

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, July 9-10, 2024, in Boston, and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference, July 15, 2024.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

EN
02/07/2024

Underlying

AUPAurinia Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aurinia Pharmaceuticals Inc.

 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat L...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN). The Company’s collaboration partner, Otsuka Pharmaceutical Co., Ltd., filed the new drug application (NDA) with Japanese regulatory authorities in November 2023. The approval is based on data from the AURORA Clinical Program, which included a 12-month, P...

September 24, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Con...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September 17-19, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found . About Aurinia Aurinia Pharmaceutica...

September 13, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Announces Board Restructuring

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has restructured its Board of Directors (the Board) to further align the Company with shareholder interests. Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director. Mr. Greenleaf had conditionally resigned as a Director because he received less than majority support at the 2024 Annual General Meeting (the Meeting). The Board carefully considered all relevant factors and determined that there are exceptional circumstan...

September 12, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 45.59
GWRE GUIDEWIRE SOFTW...
PHM PulteGroup Inc... ... (+35)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

GWRE GUIDEWIRE SOFTWARE INC
PHM PULTEGROUP INC.
ZTS ZOETIS INC. CLASS A
WWW WOLVERINE WORLD WIDE INC.
PSA PUBLIC STORAGE
MGPI MGP INGREDIENTS INC.
ERIE ERIE INDEMNITY COMPANY CLASS A
CUBE CUBESMART
CYD CHINA YUCHAI INTERNATIONAL LTD.
LFVN LIFEVANTAGE
TZOO TRAVELZOO
CYH COMMUNITY HEALTH SYSTEMS INC.
SUI SUN COMMUNITIES INC.
AUP AURINIA PHARMACEUTICALS INC.
GIII G-III APPAREL GROUP LTD.
RAIL FREIGHTCAR AMERICA INC.
FCPT FOUR CORNERS PROPERTY TRUST INC.
AGX ARGAN INC.
NATH NATHAN'S FAMOUS INC.
SBAC SBA COMMUNICATIONS CORP. CLASS A
YEXT YEXT
RYTM RHYTHM PHARMACEUTICALS
FRHC FREEDOM HOLDING CORP
TARS TARSUS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
KEQU KEWAUNEE SCIENTIFIC CORP.
ACLX ARCELLX INC
NUVL NUVALENT INC
HOI B HOI PUBLISHING AB
CMPO COMPOSECURE INC
KVUE KENVUE INC
AVBP ARRIVENT BIOPHARMA INC
FOA FINANCE OF AMERICA COMPANIES INC.
CCI CALAMOS GLB CNVRTBL & DYNMC INC COM
ASMB ASSEMBLY BIOSCIENCES INC
09/09/24 September 9, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Announces First Participant Dosed in AUR200 Single Ascending D...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025. “The start ...

September 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch